← Leaderboards
Raymond J Pickles
University Of North Carolina Chapel Hill
$6,417,208
Attributed
$9,156,555
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,156,555 · 8
By mechanism
R01$7,401,343 · 3
R21$1,755,212 · 5
Top collaborators
- Samuel Lai5 shared
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Ralph S Baric$89,182,261
- Scott H Donaldson$8,054,486
- David B Peden$24,843,616
- Michael R Knowles$33,731,453
- Wanda K O'Neal$8,008,262
Others in their field
Top investigators on “Lung”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$372,040,227
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$201,818,043
- Walter John Curran · Thomas Jefferson University$112,093,071
Research focus
LungAirway EpitheliumInfectionIn VivoCellsIn Vivo ModelVirusParainfluenza VirusRecombinantsRespiratory Syncytial VirusViralCytopathologyProteinsIn VitroIn Vitro ModelHamstersEpithelial CellsEpitheliumRespiratory VirusDoseNoseClinical TrialsEngineeringInfant
Grant awards (20)
ACE2 immunodecoys for long-lasting immunoprophylaxis against sarbecovirus and merbecoviruses that target human ACE2$2,937,578
R01 · FY2025 · AI
Engineered âmuco-trappingâ antibodies for inhaled therapy of parainfluenza and human metapneumovirus infections$535,133
R01 · FY2025 · AI
Engineered âmuco-trappingâ antibodies for inhaled therapy of parainfluenza and human metapneumovirus infections$629,240
R01 · FY2024 · AI
Engineered âmuco-trappingâ antibodies for inhaled therapy of parainfluenza and human metapneumovirus infections$688,330
R01 · FY2023 · AI
Engineered âmuco-trappingâ antibodies for inhaled therapy of parainfluenza and human metapneumovirus infections$688,413
R01 · FY2022 · AI
Genetically Engineered Hamsters as Small Animal Models for Testing RSV Therapeutics$151,475
R21 · FY2019 · AI · contact PI
Genetically Engineered Hamsters as Small Animal Models for Testing RSV Therapeutics$273,925
R21 · FY2018 · AI · contact PI
RSV, Keratins and Distal Airway Infection$228,000
R21 · FY2016 · AI · contact PI
RSV, Keratins and Distal Airway Infection$190,000
R21 · FY2015 · AI · contact PI
Why Are Steroids Ineffective at Suppressing RSV Bronchiolitis$228,000
R21 · FY2014 · AI · contact PI
Why Are Steroids Ineffective at Suppressing RSV Bronchiolitis$178,600
R21 · FY2013 · AI · contact PI
CFTR Delivery to Ciliated Airway Cells by PIV Vectors$344,505
R01 · FY2009 · HL · contact PI
CFTR Delivery to Ciliated Airway Cells by PIV Vectors$171,006
R01 · FY2009 · HL · contact PI
CFTR Delivery to Ciliated Airway Cells by PIV Vectors$344,505
R01 · FY2008 · HL · contact PI
CFTR Delivery to Ciliated Airway Cells by PIV Vectors$344,505
R01 · FY2007 · HL · contact PI
CFTR Delivery to Ciliated Airway Cells by PIV Vectors$354,795
R01 · FY2006 · HL · contact PI
Viral-Bacterial Interactions in the Airway Epithelium$178,212
R21 · FY2006 · HL · contact PI
CFTR Delivery to Ciliated Airway Cells by PIV Vectors$363,333
R01 · FY2005 · HL
Viral-Bacterial Interactions in the Airway Epithelium$182,500
R21 · FY2005 · HL
AIRWAY KININ RECEPTORS AS TARGETS FOR ADENOVIRAL VECTORS$144,500
R21 · FY2000 · DK